Celldex

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases.

CEO

Anthony S. Marucci

CEOAnthony S. Marucci

Employees

198

Employees198

Headquarters

Hampton, New Jersey

HeadquartersHampton, New Jersey

Founded

1983

Founded1983

Employees

198

Employees198

CLDX Key Statistics

Market cap

3.97B

Market cap3.97B

Price-Earnings ratio

-9.86

Price-Earnings ratio-9.86

Dividend yield

—

Dividend yield—

Average volume

954.48K

Average volume954.48K

High today

$44.60

High today$44.60

Low today

$42.46

Low today$42.46

Open price

$42.81

Open price$42.81

Volume

756.62K

Volume756.62K

52 Week high

$44.60

52 Week high$44.60

52 Week low

$19.72

52 Week low$19.72

Stock Snapshot

As of today, Celldex(CLDX) shares are valued at $44.33. The company's market cap stands at 3.97B, with a P/E ratio of -9.86.

On 2026-08-11, Celldex(CLDX) stock moved within a range of $42.46 to $44.60. With shares now at $44.33, the stock is trading +4.4% above its intraday low and -0.6% below the session's peak.

Trading volume for Celldex(CLDX) stock has reached 756.62K, versus its average volume of 954.48K.

The stock's 52-week range extends from a low of $19.72 to a high of $44.60.

CLDX News

Simply Wall St 2d

Why Celldex Therapeutics Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress

Earlier this week, Celldex Therapeutics reported its second quarter 2026 results, showing revenue of just US$22,000 and a net loss of US$73.5 million, alongside...

TipRanks 4d

Celldex: Buy Rating Reaffirmed as Strong 2Q26 Results, Robust Pipeline Support Unchanged $60 Price Target

Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Celldex and keeping the price target at $60.00. Unlock powerful investing tools with TipR...

TipRanks 4d

Barzolvolimab’s Accelerated CSU Progress and Robust Market Backdrop Underpin Maintained Buy Rating and Unchanged $56 Price Target

Celldex, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the st...

Analyst ratings

94%

of 16 ratings

Buy

93.8%

Hold

6.3%

Sell

More CLDX News

Barchart 5d

Celldex: Q2 Earnings Snapshot - Barchart.com

...

TipRanks 5d

Celldex reports Q2 EPS (94c), consensus ($1.06)

Reports Q2 revenue $22,000, consensus $857,900. “We are leaders in mast cell science with a pipeline of programs that have the potential to dramatically shift t...

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.

Plug Power

Ford Motor

Tilray Brands

Take-Two Interactive Soft…

Pfizer

General Electric

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.